General Information of DT
DT ID DTD0318
Gene Name SLC36A1
Protein Name Proton-coupled amino acid transporter 1
Gene ID
206358
UniProt ID
Q7Z2H8
TCDB ID
2.A.18.8.7
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms LYAAT1; PAT1; Proton/amino acid transporter 1; SLC36A1; Solute carrier family 36 member 1; TRAMD3; hPAT1
DT Family Amino Acid/Auxin Permease (AAAP) Family ;
Function This tranporter has a pH-dependent electrogenic transport activity for small amino acids such as glycine, alanine and proline. Besides small apolar L-amino acids, it also recognizes their D-enantiomers and selected amino acid derivatives such as gamma-aminobutyric acid.
Disease(s) Epilepsy [ICD-11: 8A6Z]
Insomnia [ICD-11: 7A0Z]
Nutritional deficiency [ICD-11: 5B7Z]
Peripheral T-cell lymphoma [ICD-11: 2A90.C]
Tuberculosis [ICD-11: 1B1Z]
Endogenous Substrate(s) H+
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT

(β) Post-translational Modification of This DT

(γ) Transcriptional Regulation of This DT

(δ) Epigenetic Regulation of This DT

(ε) Exogenous Modulation of This DT

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences

General Variability Data of This DT (VARIDT 1.0)

(β) Disease-specific Protein Abundances of This DT

(γ) Species- and Tissue-specific DT Abundances

Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

Click to Show/Hide the Full List of Drug:            6 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Amino acids
Approved Drug Info Nutritional deficiency 5B7Z [1]
Aminolevulinic acid
Approved Drug Info Photodynamic therapy EK90.0 [2]
Cycloserine
Approved Drug Info Dementia 6D8Z [3]
Glycine
Approved Drug Info Dietary shortage 5B7Z [4]
L-proline
Approved Drug Info Dietary shortage 5B7Z [5]
Vigabatrin
Approved Drug Info Infantile spasm 8A62.0 [6]

 Withdrawn, Discontinued or Preclinical Drug

Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Gaboxadol
Discontinued in Phase 3 Drug Info Insomnia 7A0Z [7]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Aminolevulinic acid
137
EM Info Identified using COS-7 cells-PAT1 [2]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Aminolevulinic acid Approved Drug Info Monkey kidney fibroblast-like cell (COS)7-hPAT1 Km = 6800 microM [2]
Vigabatrin Approved Drug Info X.Laevis oocytes-hPAT1 Km = 5200 microM [6]
References
1 Substrate specificity of the amino acid transporter PAT1. Amino Acids. 2006 Sep;31(2):111-7.
2 Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53.
3 Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). J Cell Physiol. 2005 Aug;204(2):604-13.
4 Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008 Sep 2;35(1-2):86-95.
5 PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats. Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E65-74.
6 Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res. 2012 Apr;29(4):1134-42.
7 Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009 Aug;157(8):1380-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.